Aptar

Aptar Reports Second Quarter 2026 Results ow.ly/CUtx50ZuRCX

We’re proud to share that Aptar has been named one of TIME’s World’s Most Sustainable Companies 2026 for the third consecutive year. Learn more: ow.ly/nrGI50ZtCOW #Sustainability #ProgressInMotion #ESG #Innovation #SustainableBusiness #Aptar

In this interview, Aptar Pharma and Dianosic discuss advancing intranasal drug delivery for CAR and CRS, with future potential in nose-to-brain applications. #AptarPharma #Dianosic #IntranasalDrugDelivery #NoseToBrain #Partnership #Innovation

Aptar Pharma announces MHRA GMP certification at its Nanopharm site in Wales, strengthening regulated analytical capabilities for complex inhaled and nasal medicines. Read full Press Release: ow.ly/Gfqx50Zrxzc #AptarPharma #Nanopharm #GMP

Aptar Pharma announces collaborative system-level framework for #injectabledrugdelivery systems, working with partners to develop integrated system-level testing & performance data packages to help support more informed development decisions. ow.ly/AsAO50ZoRYG #AptarPharma

Aptar Declares Quarterly Dividend ow.ly/sIRs50ZoEqR

Unlock the full potential of your dermal drug products with #AptarPharma. Our expertise in dermal drug delivery helps supports the acceleration and derisking of combination product development, from formulation to patient. To find out more, visit: ow.ly/b8ql50ZocL8

We are among the Top 100 of TIME's America's Best Companies 2026. Aptar is ranked #83, in the top 5 companies in the Engineering, Manufacturing and Medical Technology category and among the top 10 companies nationwide for sustainability transparency. ow.ly/1HFU50Zn6IC

Today on #WorldSkinHealthDay, #AptarPharma supports global efforts to raise awareness of skin health. Together with our customers and partners, we help advance innovation in #dermaldrugdelivery to improve patient experiences worldwide. #SkinHealth

Thanks to everyone who met with the Aptar Pharma team at #FCEPharma 2026 in São Paulo. Hear from members of our LATAM team and Sommaplast in our wrap-up video as they reflect on the value of connecting face-to-face with customers and partners. #AptarPharma #DrugDelivery

It's #WorldAllergyAwarenessWeek and AptarPharma joins the #WorldAllergyOrganization in highlighting an important message: Allergy Care is Essential Care. Learn how we're helping advance #allergicrhinitis treatments through #nasaldrugdelivery: ow.ly/WmjJ50Zg6Em #WAO75

Recently, our Board of Director, George Fotiades and CHRO, Shiela Vinczeller, spoke at the NextUp Learning Week event. NextUp brings together a community dedicated to building the next generation of leaders. Learn more about career development at Aptar: ow.ly/NEIi50ZeEJJ

We’re proud to share Aptar’s 2025 Corporate Sustainability Report. This year’s report reflects momentum across our global operations, showing how our teams continue to turn our efforts into measurable progress. View the report here: #Aptar #Sustainability

Excited to have our CEO, Stephan Tanda, recognized along with so many other inspiring business leaders as an award winner in the Entrepreneur Of The Year® Midwest program! On to the National Awards! #EOYUS #EOYMW@ EY_US ow.ly/Ux6C50ZbllR

Heading to BIO International Convention 2026 in San Diego, June 22–25? So are we! Stop by Booth 5956 to meet with our experts from #AptarPharma and #GatewayAnalytical and explore how we can support your drug development, from formulation to patient. #BIO2026 #DrugDevelopment

Aptar is pleased to share that our President and CEO, Stephan Tanda, has been named a Midwest finalist for the Entrepreneur of the Year® 2026 Award. Congratulations Stephan, thank you for your leadership and focus on innovation! ow.ly/8TCL50Z7HR5

Aptar Pharma announces three new international patent applications focused on inhaled and nasal GLP-1 delivery, strengthening its capabilities in biologics delivery. Read full press release - ow.ly/NMgN50Z55g2 #DrugDelivery #Innovation #GLP1 #Biologics

Aptar’s EVP & CFO, Vanessa Kanu, was recently featured in an article by CPA Ontario. In the feature, Vanessa shares her perspective on the evolving role of the CFO. Read the full article here: ow.ly/3roH50Z099n

Interest in #NoseToBrain delivery is accelerating - but reliable delivery remains a key challenge. In this Q&A, Reenal Gandhi shares insights on anatomy, delivery variability & why device–formulation alignment matters. ow.ly/vfwO50YWq2L #CNS #DrugDelivery #AptarPharma

A recap from #ARVO2026. Thank you to everyone who visited Aptar Pharma's booth and connected with us during this year’s event. Watch our recap video for highlights from the conversations and innovation shared in eye care. #AptarPharma #Ophthalmology #PreservativeFree